Alphabet's AI biotech Isomorphic Labs bags $2.1B series B to fuel next-gen drug design model - Fierce Biotech

Isomorphic Labs, the AI biotech subsidiary of Alphabet, has raised a $2.1 billion Series B funding round. The company announced the round in a press release on Thursday. The funding is intended to support the development and deployment of IsoDDE, the company's AI drug design engine, and to accelerate its in-house drug pipeline.

The Series B round was led by a group of investors that the company did not name in its announcement. Isomorphic Labs plans to use the capital to expand its team, increase computational capacity, and advance multiple drug programs toward clinical trials. The company stated that IsoDDE is designed to 'model molecular interactions at unprecedented scale and precision.'

This is one of the largest private fundraising rounds in the AI drug discovery sector. The company has not yet disclosed details of its current pipeline or any lead compounds that have entered clinical testing.